US Bancorp DE Has $1.10 Million Position in Supernus Pharmaceuticals Inc (SUPN)

US Bancorp DE reduced its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 13.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,692 shares of the specialty pharmaceutical company’s stock after selling 4,391 shares during the period. US Bancorp DE’s holdings in Supernus Pharmaceuticals were worth $1,104,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parametrica Management Ltd purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $247,000. Quantbot Technologies LP purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $248,000. Alpha Cubed Investments LLC purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $254,000. Winslow Evans & Crocker Inc. purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $273,000. Finally, Intrust Bank NA raised its holdings in Supernus Pharmaceuticals by 37.6% during the third quarter. Intrust Bank NA now owns 6,957 shares of the specialty pharmaceutical company’s stock worth $278,000 after purchasing an additional 1,901 shares in the last quarter. 98.37% of the stock is owned by hedge funds and other institutional investors.

SUPN has been the subject of several analyst reports. BidaskClub cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 1st. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 price target for the company in a report on Wednesday, November 8th. ValuEngine cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 1st. B. Riley increased their price target on shares of Supernus Pharmaceuticals from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, December 28th. Finally, Piper Jaffray Companies set a $41.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, October 29th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $51.36.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.04, for a total transaction of $960,800.00. Following the completion of the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at $1,561,300. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 165,750 shares of company stock valued at $7,133,973. 6.70% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $37.25 on Wednesday. Supernus Pharmaceuticals Inc has a 1-year low of $24.65 and a 1-year high of $50.04. The stock has a market cap of $1,965.90, a PE ratio of 36.18 and a beta of 1.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts predict that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/us-bancorp-de-has-1-10-million-position-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply